{"analyses":[{"groupDescription":"2 treatment, 2 periiod cross-over analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"ANOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.5","upperLimit":"5.7","value":"5.1"},{"groupId":"OG001","lowerLimit":"8.4","upperLimit":"10.5","value":"9.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"Time (in days) to first G-CSF dose","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive filgrastim SC QD started at 24 hours after completion of chemotherapy and continued daily until ANC reaches at least 1,000/uL post nadir.","id":"OG000","title":"Arm I (Fixed Filgrastim)"},{"description":"Patients receive filgrastim SC QD started on the first day after chemotherapy when ANC falls below 1,000/uL and stopped when ANC reaches at least 1,000/uL post nadir.","id":"OG001","title":"Arm II (Flexible Filgrastim)"}],"paramType":"MEAN","populationDescription":"All participants with period 2 data","reportingStatus":"POSTED","timeFrame":"time to ANC 1000","title":"Days to First G-CSF Dose","type":"SECONDARY","unitOfMeasure":"days"}